Skip to main content

Table 7 Percentage growth inhibitory effect of herbal combination against different human cell lines

From: Development of aqueous-based multi-herbal combination using principal component analysis and its functional significance in HepG2 cells

Conc. (μg/ml) MCa NMCb
MG-63 IMR-32 HeLa A-549 HepG2 293 T
Inhibition (% ± SE)
31.25 32.947 ± 0.809 08.141 ± 1.339 13.583 ± 0.676 15.487 ± 0.366 36.338 ± 0.972 1.695 ± 0.676
62.5 34.090 ± 0.024 20.261 ± 0.235 31.336 ± 0.821 27.051 ± 1.012 44.376 ± 0.570 2.452 ± 0.567
125 37.926 ± 0.280 32.510 ± 0.284 34.619 ± 0.911 46.275 ± 0.411 60.264 ± 0.247 5.510 ± 0.440
250 41.271 ± 0.512 50.335 ± 0.598 47.664 ± 0.903 60.716 ± 0.171 67.763 ± 0.027 7.206 ± 0.621
500 51.194 ± 0.537 63.810 ± 0.402 59.736 ± 0.671 68.883 ± 0.230 84.514 ± 0.021 8.689 ± 0.813
1000 75.440 ± 0.368 71.598 ± 0.257 63.992 ± 0.677 74.007 ± 0.106 95.448 ± 0.011 9.658 ± 0.424
Regression equation y = 0.043x + 31.28 y = 19.19ln(x) - 58.24 y = 14.43ln(x) - 32.89 y = 17.82ln(x) - 43.52 y = 17.45ln(x) - 25.54 y = 2.482ln(x) - 6.976
R2 0.995 0.991 0.970 0.964 0.991 0.971
IC50 (μg/ml) 435.349 281.586 312.399 189.025 75.864 9.322 × 109
Camptothecin (10 μM) 81.86 65.68 71.60 68.07 68.13 22.62
  1. aMalignant cells; bNon-malignant cell